LLY

970.81

+5.25%↑

JNJ

186.35

+0.03%↑

UNH

319.3

-1.48%↓

NVS

126.62

+0.27%↑

ABT

125.16

-0.82%↓

LLY

970.81

+5.25%↑

JNJ

186.35

+0.03%↑

UNH

319.3

-1.48%↓

NVS

126.62

+0.27%↑

ABT

125.16

-0.82%↓

LLY

970.81

+5.25%↑

JNJ

186.35

+0.03%↑

UNH

319.3

-1.48%↓

NVS

126.62

+0.27%↑

ABT

125.16

-0.82%↓

LLY

970.81

+5.25%↑

JNJ

186.35

+0.03%↑

UNH

319.3

-1.48%↓

NVS

126.62

+0.27%↑

ABT

125.16

-0.82%↓

LLY

970.81

+5.25%↑

JNJ

186.35

+0.03%↑

UNH

319.3

-1.48%↓

NVS

126.62

+0.27%↑

ABT

125.16

-0.82%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

SectorHealthcare

21.6 -1.37

Buy Sell

Overview

Share price change

24h

Current

Min

21.53

Max

21.95

Key metrics
By Trading Economics
Income	7.7M -41M
Sales	3.5M 110M
Profit margin	-37.032
Employees	1,869
EBITDA	1.4M -55M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+145.34% upside

Market Stats
By TradingEconomics
Market Cap	-1.2B 3B
Previous open	22.97
Previous close	21.6

News Sentiment

By Acuity

31%

69%

80 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lis 2025, 21:36 UTC

Earnings

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 lis 2025, 21:22 UTC

Earnings

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 lis 2025, 00:00 UTC

Market Talk

India Inflation Poised to Hit New Low -- Market Talk

9 lis 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 lis 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 lis 2025, 21:05 UTC

Earnings

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 lis 2025, 21:04 UTC

Earnings

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 lis 2025, 21:03 UTC

Earnings

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 lis 2025, 20:49 UTC

Earnings

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 lis 2025, 20:49 UTC

Earnings

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 lis 2025, 20:45 UTC

Earnings

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 lis 2025, 20:45 UTC

Earnings

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 lis 2025, 20:42 UTC

Earnings

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 lis 2025, 20:42 UTC

Earnings

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 lis 2025, 20:41 UTC

Earnings

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 lis 2025, 20:41 UTC

Earnings

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 lis 2025, 20:39 UTC

Earnings

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 lis 2025, 20:39 UTC

Earnings

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 lis 2025, 20:38 UTC

Earnings

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 lis 2025, 13:10 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 lis 2025, 03:50 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 lis 2025, 03:41 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 lis 2025, 03:07 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 lis 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 lis 2025, 22:22 UTC

Earnings

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Rev $2.95B >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Net $210M >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q EPS $9.89 >CSU.T

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

145.34% upside

12 Months Forecast

Average 53.73 USD 145.34%

High 74 USD

Low 25.7 USD

Based on 7 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

80 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.